Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 5
1982 1
1983 5
1984 1
1985 5
1986 5
1987 7
1988 6
1989 8
1990 10
1991 11
1992 14
1993 18
1994 8
1995 20
1996 13
1997 13
1998 17
1999 23
2000 19
2001 19
2002 28
2003 30
2004 64
2005 88
2006 98
2007 113
2008 135
2009 168
2010 188
2011 197
2012 187
2013 211
2014 203
2015 209
2016 212
2017 244
2018 277
2019 309
2020 356
2021 391
2022 404
2023 192

Text availability

Article attribute

Article type

Publication date

Search Results

4,125 results

Results by year

Filters applied: . Clear all
Page 1
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.
Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ. Li XY, et al. J Clin Invest. 2022 Mar 15;132(6):e159825. doi: 10.1172/JCI159825. J Clin Invest. 2022. PMID: 35289314 Free PMC article. No abstract available.
Helicobacter Pylori and Autoimmune Diseases: Involving Multiple Systems.
Wang L, Cao ZM, Zhang LL, Dai XC, Liu ZJ, Zeng YX, Li XY, Wu QJ, Lv WL. Wang L, et al. Among authors: li xy. Front Immunol. 2022 Feb 10;13:833424. doi: 10.3389/fimmu.2022.833424. eCollection 2022. Front Immunol. 2022. PMID: 35222423 Free PMC article. Review.
CD155 in tumor progression and targeted therapy.
Zhan M, Zhang Z, Zhao X, Zhang Y, Liu T, Lu L, Li XY. Zhan M, et al. Among authors: li xy. Cancer Lett. 2022 Oct 1;545:215830. doi: 10.1016/j.canlet.2022.215830. Epub 2022 Jul 20. Cancer Lett. 2022. PMID: 35870689 Review.
Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
Li W, Duan X, Chen X, Zhan M, Peng H, Meng Y, Li X, Li XY, Pang G, Dou X. Li W, et al. Among authors: li xy. Front Immunol. 2023 Jan 11;13:1079515. doi: 10.3389/fimmu.2022.1079515. eCollection 2022. Front Immunol. 2023. PMID: 36713430 Free PMC article. Review.
4,125 results